Key takeaways
Orilissa (elagolix) and Myfembree (relugolix / estradiol / norethindrone) are both medications used to relieve pain from endometriosis, but they belong to different medication classes. Orilissa is a gonadotropin-releasing hormone (GnRH) antagonist, while Myfembree combines a GnRH antagonist with estrogen and progestin. Orilissa is specifically FDA-approved for moderate-to-severe pain caused by endometriosis, whereas Myfembree is approved for both endometriosis pain and heavy menstrual bleeding related to uterine fibroids. Orilissa is taken once or twice daily, while Myfembree is taken once daily. Common side effects of Orilissa include hot flashes and headaches. Myfembree can cause similar side effects, but it also has a risk of blood clots, heart attacks, and strokes. Both medications can lead to bone loss with long-term use, so they are typically limited to a maximum of 2 years of treatment. Additionally, both medications can interact with hormonal birth control and are not recommended during pregnancy, so it's important to use non-hormonal birth control while taking either medication.
